Do analysts prefer KZIA or INM?

Novogen presently has a consensus target price of $21.00, indicating a potential upside of 82.61%. Given Novogen's stronger consensus rating and higher possible upside, analysts plainly believe Novogen is more favorable than InMed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Novogen 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, KZIA or INM?

InMed Pharmaceuticals has higher revenue and earnings than Novogen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novogen $30K 632.50 -$13.41M N/A N/A InMed Pharmaceuticals $4.94M 1.01 -$8.16M -$2.89 N/A

Do analysts prefer INM or TPST?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Do analysts prefer INM or XCUR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer CLRB or INM?

Cellectar Biosciences currently has a consensus price target of $11.00, suggesting a potential upside of 386.73%. Given Cellectar Biosciences' stronger consensus rating and higher probable upside, research analysts clearly believe Cellectar Biosciences is more favorable than InMed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cellectar Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend INM or MDCX?

Medicus Pharma has a consensus target price of $9.00, indicating a potential upside of 2,712.50%. Given Medicus Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Medicus Pharma is more favorable than InMed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Medicus Pharma 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

InMed Pharmaceuticals (INM) Competitors

$1.51 -0.02 (-1.31%)

Closing price 04:00 PM Eastern

Extended Trading

$1.48 -0.02 (-1.66%)

As of 06:04 PM Eastern

Compare

INM vs. KZIA, TPST, XCUR, CLRB, and MDCX

Should you buy InMed Pharmaceuticals stock or one of its competitors? MarketBeat compares InMed Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with InMed Pharmaceuticals include Novogen (KZIA), Tempest Therapeutics (TPST), Exicure (XCUR), Cellectar Biosciences (CLRB), and Medicus Pharma (MDCX). These companies are all part of the "pharmaceutical products" industry.

How does InMed Pharmaceuticals compare to Novogen?

Novogen (NASDAQ:KZIA) and InMed Pharmaceuticals (NASDAQ:INM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.

30.9% of Novogen shares are owned by institutional investors. Comparatively, 20.1% of InMed Pharmaceuticals shares are owned by institutional investors. 1.0% of Novogen shares are owned by insiders. Comparatively, 0.9% of InMed Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

InMed Pharmaceuticals has higher revenue and earnings than Novogen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novogen	$30K	632.50	-$13.41M	N/A	N/A
InMed Pharmaceuticals	$4.94M	1.01	-$8.16M	-$2.89	N/A

Novogen presently has a consensus target price of $21.00, indicating a potential upside of 82.61%. Given Novogen's stronger consensus rating and higher possible upside, analysts plainly believe Novogen is more favorable than InMed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novogen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Novogen has a beta of 2.17, meaning that its stock price is 117% more volatile than the broader market. Comparatively, InMed Pharmaceuticals has a beta of 0.98, meaning that its stock price is 2% less volatile than the broader market.

In the previous week, Novogen and Novogen both had 2 articles in the media. Novogen's average media sentiment score of 0.62 beat InMed Pharmaceuticals' score of 0.29 indicating that Novogen is being referred to more favorably in the media.

Company	Overall Sentiment
Novogen	Positive
InMed Pharmaceuticals	Neutral

Novogen has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -132.87%. Novogen's return on equity of 0.00% beat InMed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novogen	N/A	N/A	N/A
InMed Pharmaceuticals	-132.87%	-80.85%	-68.11%

Summary

Novogen beats InMed Pharmaceuticals on 11 of the 13 factors compared between the two stocks.

How does InMed Pharmaceuticals compare to Tempest Therapeutics?

InMed Pharmaceuticals (NASDAQ:INM) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

In the previous week, Tempest Therapeutics had 1 more articles in the media than InMed Pharmaceuticals. MarketBeat recorded 3 mentions for Tempest Therapeutics and 2 mentions for InMed Pharmaceuticals. Tempest Therapeutics' average media sentiment score of 1.28 beat InMed Pharmaceuticals' score of 0.29 indicating that Tempest Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
InMed Pharmaceuticals	Neutral
Tempest Therapeutics	Positive

20.1% of InMed Pharmaceuticals shares are owned by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are owned by institutional investors. 0.9% of InMed Pharmaceuticals shares are owned by company insiders. Comparatively, 6.3% of Tempest Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

InMed Pharmaceuticals has higher revenue and earnings than Tempest Therapeutics. InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMed Pharmaceuticals	$4.94M	1.01	-$8.16M	-$2.89	N/A
Tempest Therapeutics	N/A	N/A	-$26.26M	-$6.01	N/A

Tempest Therapeutics has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -132.87%. InMed Pharmaceuticals' return on equity of -80.85% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InMed Pharmaceuticals	-132.87%	-80.85%	-68.11%
Tempest Therapeutics	N/A	-355.61%	-121.21%

InMed Pharmaceuticals has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market. Comparatively, Tempest Therapeutics has a beta of -1.85, suggesting that its stock price is 285% less volatile than the broader market.

Summary

Tempest Therapeutics beats InMed Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does InMed Pharmaceuticals compare to Exicure?

InMed Pharmaceuticals (NASDAQ:INM) and Exicure (NASDAQ:XCUR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, media sentiment and earnings.

Exicure has lower revenue, but higher earnings than InMed Pharmaceuticals. Exicure is trading at a lower price-to-earnings ratio than InMed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMed Pharmaceuticals	$4.94M	1.01	-$8.16M	-$2.89	N/A
Exicure	$500K	35.16	-$4.95M	-$1.55	N/A

20.1% of InMed Pharmaceuticals shares are owned by institutional investors. Comparatively, 42.8% of Exicure shares are owned by institutional investors. 0.9% of InMed Pharmaceuticals shares are owned by insiders. Comparatively, 52.8% of Exicure shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Exicure has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -132.87%. InMed Pharmaceuticals' return on equity of -80.85% beat Exicure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InMed Pharmaceuticals	-132.87%	-80.85%	-68.11%
Exicure	N/A	-179.41%	-64.37%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

InMed Pharmaceuticals has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market. Comparatively, Exicure has a beta of 3.53, suggesting that its share price is 253% more volatile than the broader market.

In the previous week, Exicure had 1 more articles in the media than InMed Pharmaceuticals. MarketBeat recorded 3 mentions for Exicure and 2 mentions for InMed Pharmaceuticals. Exicure's average media sentiment score of 1.43 beat InMed Pharmaceuticals' score of 0.29 indicating that Exicure is being referred to more favorably in the news media.

Company	Overall Sentiment
InMed Pharmaceuticals	Neutral
Exicure	Positive

Summary

Exicure beats InMed Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

How does InMed Pharmaceuticals compare to Cellectar Biosciences?

Cellectar Biosciences (NASDAQ:CLRB) and InMed Pharmaceuticals (NASDAQ:INM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends, earnings and media sentiment.

InMed Pharmaceuticals has higher revenue and earnings than Cellectar Biosciences. InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectar Biosciences	N/A	N/A	-$21.79M	-$6.66	N/A
InMed Pharmaceuticals	$4.94M	1.01	-$8.16M	-$2.89	N/A

In the previous week, Cellectar Biosciences and Cellectar Biosciences both had 2 articles in the media. Cellectar Biosciences' average media sentiment score of 1.43 beat InMed Pharmaceuticals' score of 0.29 indicating that Cellectar Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Cellectar Biosciences	Positive
InMed Pharmaceuticals	Neutral

Cellectar Biosciences has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -132.87%. InMed Pharmaceuticals' return on equity of -80.85% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectar Biosciences	N/A	-349.24%	-153.18%
InMed Pharmaceuticals	-132.87%	-80.85%	-68.11%

Cellectar Biosciences currently has a consensus price target of $11.00, suggesting a potential upside of 386.73%. Given Cellectar Biosciences' stronger consensus rating and higher probable upside, research analysts clearly believe Cellectar Biosciences is more favorable than InMed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

16.4% of Cellectar Biosciences shares are owned by institutional investors. Comparatively, 20.1% of InMed Pharmaceuticals shares are owned by institutional investors. 2.6% of Cellectar Biosciences shares are owned by insiders. Comparatively, 0.9% of InMed Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Cellectar Biosciences has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market. Comparatively, InMed Pharmaceuticals has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market.

Summary

Cellectar Biosciences and InMed Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does InMed Pharmaceuticals compare to Medicus Pharma?

InMed Pharmaceuticals (NASDAQ:INM) and Medicus Pharma (NASDAQ:MDCX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

InMed Pharmaceuticals has a beta of 0.98, meaning that its stock price is 2% less volatile than the broader market. Comparatively, Medicus Pharma has a beta of 0.14, meaning that its stock price is 86% less volatile than the broader market.

In the previous week, Medicus Pharma had 8 more articles in the media than InMed Pharmaceuticals. MarketBeat recorded 10 mentions for Medicus Pharma and 2 mentions for InMed Pharmaceuticals. InMed Pharmaceuticals' average media sentiment score of 0.29 beat Medicus Pharma's score of 0.27 indicating that InMed Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
InMed Pharmaceuticals	Neutral
Medicus Pharma	Neutral

20.1% of InMed Pharmaceuticals shares are owned by institutional investors. 0.9% of InMed Pharmaceuticals shares are owned by company insiders. Comparatively, 8.1% of Medicus Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Medicus Pharma has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -132.87%. InMed Pharmaceuticals' return on equity of -80.85% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InMed Pharmaceuticals	-132.87%	-80.85%	-68.11%
Medicus Pharma	N/A	-3,137.84%	-311.33%

Medicus Pharma has a consensus target price of $9.00, indicating a potential upside of 2,712.50%. Given Medicus Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Medicus Pharma is more favorable than InMed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Medicus Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

InMed Pharmaceuticals has higher revenue and earnings than Medicus Pharma. InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMed Pharmaceuticals	$4.94M	1.01	-$8.16M	-$2.89	N/A
Medicus Pharma	N/A	N/A	-$35.46M	-$2.68	N/A

Summary

Medicus Pharma beats InMed Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Get InMed Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INM vs. The Competition

Export

Metric	InMed Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.00M	$2.94B	$6.43B	$11.71B
Dividend Yield	N/A	1.71%	2.67%	5.55%
P/E Ratio	-0.52	17.80	24.46	23.62
Price / Sales	1.01	289.23	500.50	105.27
Price / Cash	N/A	55.74	42.36	56.09
Price / Book	0.23	3.88	10.43	6.70
Net Income	-$8.16M	$75.85M	$3.56B	$337.26M
7 Day Performance	-4.13%	-1.87%	-1.39%	-1.41%
1 Month Performance	132.31%	-6.20%	0.86%	1.15%
1 Year Performance	-45.49%	12.60%	19.42%	22.61%

InMed Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INM InMed Pharmaceuticals	1.3713 of 5 stars	$1.51 -1.3%	N/A	-46.3%	$5.00M	$4.94M	N/A	10	Short Interest Increase Gap Down
KZIA Novogen	1.9687 of 5 stars	$11.63 +1.9%	$21.00 +80.5%	+115.5%	$19.15M	$30K	N/A	12	News Coverage Gap Up
TPST Tempest Therapeutics	2.6977 of 5 stars	$1.30 +2.3%	N/A	-85.8%	$19.11M	N/A	N/A	20	Positive News
XCUR Exicure	1.2498 of 5 stars	$2.93 +2.6%	N/A	-70.6%	$18.63M	$500K	N/A	50	News Coverage Positive News Short Interest Decrease
CLRB Cellectar Biosciences	4.5569 of 5 stars	$2.31 -2.2%	$11.00 +376.8%	-77.8%	$18.46M	N/A	N/A	10	Positive News Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INM) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

InMed Pharmaceuticals (INM) Competitors

INM vs. KZIA, TPST, XCUR, CLRB, and MDCX

How does InMed Pharmaceuticals compare to Novogen?

Summary

How does InMed Pharmaceuticals compare to Tempest Therapeutics?

Summary

How does InMed Pharmaceuticals compare to Exicure?

Summary

How does InMed Pharmaceuticals compare to Cellectar Biosciences?

Summary

How does InMed Pharmaceuticals compare to Medicus Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INM vs. The Competition

InMed Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

InMed Pharmaceuticals (INM) Competitors

INM vs. KZIA, TPST, XCUR, CLRB, and MDCX

How does InMed Pharmaceuticals compare to Novogen?

Do institutionals & insiders believe in KZIA or INM?

Which has preferable valuation and earnings, KZIA or INM?

Do analysts prefer KZIA or INM?

Which has more volatility and risk, KZIA or INM?

Does the media prefer KZIA or INM?

Is KZIA or INM more profitable?

Summary

How does InMed Pharmaceuticals compare to Tempest Therapeutics?

Does the media favor INM or TPST?

Do insiders and institutionals have more ownership in INM or TPST?

Do analysts prefer INM or TPST?

Which has preferable earnings and valuation, INM or TPST?

Is INM or TPST more profitable?

Which has more volatility & risk, INM or TPST?

Summary

How does InMed Pharmaceuticals compare to Exicure?

Which has stronger valuation and earnings, INM or XCUR?

Do insiders & institutionals have more ownership in INM or XCUR?

Is INM or XCUR more profitable?

Do analysts prefer INM or XCUR?

Which has more risk and volatility, INM or XCUR?

Does the media refer more to INM or XCUR?

Summary

How does InMed Pharmaceuticals compare to Cellectar Biosciences?

Which has preferable valuation & earnings, CLRB or INM?

Does the media prefer CLRB or INM?

Is CLRB or INM more profitable?

Do analysts prefer CLRB or INM?

Do institutionals and insiders hold more shares of CLRB or INM?

Which has more volatility and risk, CLRB or INM?

Summary

How does InMed Pharmaceuticals compare to Medicus Pharma?

Which has more risk and volatility, INM or MDCX?

Does the media favor INM or MDCX?

Do institutionals and insiders believe in INM or MDCX?

Is INM or MDCX more profitable?

Do analysts recommend INM or MDCX?

Which has stronger earnings and valuation, INM or MDCX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INM vs. The Competition

InMed Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools